Cantargia (OM:CANTA BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CANTA BTA Stock Overview

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases.

CANTA BTA fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 87.1% below our estimate of its fair value

Revenue is forecast to grow 107.98% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK0)

Shares are highly illiquid

Does not have a meaningful market cap (SEK512M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Cantargia AB (publ) Competitors

SynAct Pharma

OM:SYNACT

kr576.2m

Curasight

NGM:CURAS

kr.387.9m

Initiator Pharma

OM:INIT

kr493.2m

Xbrane Biopharma

OM:XBRANE

kr609.5m

Price History & Performance

Summary of all time highs, changes and price drops for Cantargia
Historical stock prices
Current Share Price	kr5.01
52 Week High	kr5.08
52 Week Low	kr4.85
Beta	1.48
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.11%

Recent updates

Shareholder Returns

	CANTA BTA	SE Biotechs	SE Market
7D	n/a	3.9%	1.0%
1Y	n/a	-6.6%	-1.1%

Return vs Industry: Insufficient data to determine how CANTA BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how CANTA BTA performed against the Swedish Market.

Price Volatility

Is CANTA BTA's price volatile compared to industry and market?
CANTA BTA volatility
CANTA BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.9%
Market Average Movement	6.2%
10% most volatile stocks in SE Market	12.0%
10% least volatile stocks in SE Market	3.6%

Stable Share Price: Insufficient data to determine CANTA BTA's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine CANTA BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	28	Goran Forsberg	https://www.cantargia.com

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP.

Cantargia AB (publ) Fundamentals Summary

How do Cantargia's earnings and revenue compare to its market cap?
CANTA BTA fundamental statistics
Market Cap	kr512.49m
Earnings (TTM)	-kr411.37m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is CANTA BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CANTA BTA income statement (TTM)
Revenue	kr0
Cost of Revenue	kr0
Gross Profit	kr0
Other Expenses	kr411.37m
Earnings	-kr411.37m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 30, 2022

Earnings per share (EPS)	-4.11
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did CANTA BTA perform over the long term?

See historical performance and comparison

Cantargia OM:CANTA BTA Stock Report